Article: Nicotinamide Riboside and Calorie Restriction Improve Gut Microbiota and Reduce Liver Fat and Inflammation: Preclinical Findings

PrevNext
Digestive/Gut Health Liver Health Obesity Preclinical

Nicotinamide Riboside and Calorie Restriction Improve Gut Microbiota and Reduce Liver Fat and Inflammation: Preclinical Findings

Synopsis

Metabolic dysfunction–related fatty liver disease currently has no specific therapy. This study tested nicotinamide riboside (NR) and dietary restriction (DR) in rats with diet-induced obesity. High-fat cafeteria diets caused liver fat buildup, inflammation, and fibrosis, while DR delayed most liver problems. NR specifically reduced liver fat, cholesterol, and collagen buildup and limited harmful gut bacteria. Combining NR with DR also decreased liver size and inflammation. These findings suggest that NR may help protect the liver and support dietary strategies in fatty liver disease.

Journal

Nutrition

Share

Read more

Healthy Aging & Longevity

Nicotinamide Riboside Supplementation Partially Restores Sense of Smell in Aging: Preclinical Findings

SynopsisLoss of smell is an early and common feature of both aging and neurodegenerative diseases such as Alzheimer's and Parkinson's. This study investigated behavioral and molecular changes in th...

Read more
Liver Health

Nicotinamide Riboside Corrects Metabolic Imbalances and Mitochondrial Dysfunction in Citrin Deficiency: Preclinical Findings

SynopsisCitrin deficiency (CD) is a genetic metabolic disorder caused by loss of the mitochondrial transporter CITRIN, which plays a role in the urea cycle and malate–aspartate shuttle. Patients wi...

Read more